Get the Stockscreener App
11.91
1.98%
-0.24
After Hours:
11.99
0.08
+0.67%
Omeros Corporation stock is traded at $11.91, with a volume of 1.03M.
It is down -1.98% in the last 24 hours and up +184.25% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$12.15
Open:
$11.89
24h Volume:
1.03M
Relative Volume:
1.61
Market Cap:
$701.19M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
18.61
EPS:
0.64
Net Cash Flow:
$74.30M
1W Performance:
+97.51%
1M Performance:
+184.25%
6M Performance:
+255.52%
1Y Performance:
+492.54%
1-Day Range:
$11.27
$12.26
1-Week Range:
$6.06
$12.49
52-Week Range:
$1.93
$12.49
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.91 | 701.19M | 0 | -117.81M | 74.30M | 0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
Omeros (NASDAQ:OMER) Hits New 12-Month HighHere's Why - MarketBeat
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News - Yahoo Finance
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
Omeros nears resubmission of narsoplimab BLA By Investing.com - Investing.com South Africa
Omeros nears resubmission of narsoplimab BLA - Investing.com India
Omeros stock soars to 52-week high, hits $7.53 - Investing.com
Omeros stock soars to 52-week high, hits $7.53 By Investing.com - Investing.com UK
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha
Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World
SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News
United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
Omeros Corporation (NASDAQ:OMER) Q3 2024 Earnings Call Transcript - Insider Monkey
Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat
Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada
Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia
Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India
Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com
Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Omeros stock soars to 52-week high, hits $5.68 - Investing.com
500: Something went wrong - Investing.com UK
U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn
Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros initiated with a Buy at Rodman & Renshaw - TipRanks
Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Omeros: Q3 Earnings Snapshot - New Haven Register
Omeros Corporation Reports Third Quarter 2024 Financial Results - BioSpace
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance
Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks
Omeros up 4% as Q3 results beat on EPS - MSN
Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks
Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan
Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com
Earnings Outlook For Omeros - Benzinga
Omeros (OMER) Set to Announce Earnings on Wednesday - MarketBeat
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 - Business Wire
Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews
Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):